![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 23, 2024
The co-chairs reflect on the past year in cancer research and make the case for embracing the inclusion of real-world data in ECOG-ACRIN
December 23, 2024
This phase 2 study will test a new treatment combination for patients with certain subtypes of relapsed or refractory B-cell lymphoma
December 23, 2024
Julie Brahmer, Naomi Haas, and Jedd Wolchok offer insights into a complicated issue that pertains to biomarker testing for treatment selection
December 23, 2024
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
December 23, 2024
Summaries of presentations at the 2024 San Antonio Breast Cancer Symposium as well as the 66th American Society of Hematology Annual Meeting and Exposition in San Diego
December 23, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
November 25, 2024
Fall Group Meeting highlights; impactful results in head and neck cancer; a ComboMATCH update
November 25, 2024
Several themes emerged as key areas of focus for ECOG-ACRIN during the Fall 2024 Group Meeting
November 25, 2024
In an annual evaluation, 54 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 25, 2024
EA5162 is testing a new therapy for certain patients with advanced NSCLC who have developed resistance to other treatments
November 25, 2024
October 17, 2024
The co-chairs reflect on how the cancer research landscape has evolved over the last five years